Edmonton, Alberta, Canada/April 10, 2023- Pacylex Pharmaceuticals today announced it will be presenting at two exclusive life science startup events in Canada in April, spotlighting its emergence as one of the premier Canadian biotech startup companies. Pacylex is focused on innovative research and development and is a leader in the maturing Canadian biotech ecosystem.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

• Pacylex was selected by a panel of pharmaceutical industry professionals to be one of 16 Canadian companies to present at the 3rd annual Sweet Biopharma Day, an invitation-only event, on April 12, 2023.
• Pacylex will also present at the invitation-only CDL-Vancouver's Alumni Showcase on April 19, 2023.
• In between these events, Pacylex will present exciting new scientific results at the AACR Annual meeting in Orlando, Florida.

Click image above to view full announcement.

About PCLX-001PCLX-001 is a first-in-class, oral, small molecule N-myristoyltransferase (NMT) inhibitor being developed to treat patients with leukemia and lymphoma. PCLX-001 selectively kills cancer cells in vitro and has been shown to regress hematologic malignancies and inhibit the growth of lung and breast cancer tumors in animal models. PCLX-001 appears to be particularly effective against AML stem cells in animal disease models. PCLX-001 is currently being studied in patients with Non-Hodgkin's Lymphoma (NHL) and solid tumor malignancies. More than 20 patients with cancer have received PCLX-001 with no dose limiting toxicities.

About Pacylex Pharmaceuticals

Pacylex is a clinical-stage pharmaceutical company headquartered in Edmonton, Alberta, Canada, targeting hematologic and solid cancers with a first-in-class, oral, once daily therapeutic, PCLX-001. Pacylex has a US Subsidiary in the San Francisco Bay area. PCLX-001 is the lead drug in a new class of N-myristoyltransferase (NMT) inhibitors, enabling Pacylex to exploit NMTs as new clinical targets for cancer treatment. Pacylex is conducting a multi-center Phase 1 multiple ascending dose study in Canada in patients with Diffuse Large B Cell Lymphoma (DLBCL) and solid tumors, and a Phase 2a dose expansion in patients with Non Hodgkin Lymphoma (NHL) is planned to start in Q2 2023 (ClinicalTrials.gov Identifier: NCT04836195). A Phase 1/2a clinical study in patients with Acute Myeloid Leukemia (AML) is also planned to start in Q2 2023. The US Department of Defense is supporting the initial clinical investigation of PCLX-001 in patients with AML. The FDA has granted PCLX-001 both Orphan Drug Designation and Fast Track Designation for AML. Pacylex received support from an Alberta Innovates AICE grant in 2020, and the research leading to this breakthrough was supported in part by the Alberta Cancer Foundation and the Cure Cancer Foundation. For additional information, please visit www.pacylex.com.

For more information:Pacylex Pharmaceuticals Contact: Michael J. WeickertCEO, Pacylex Pharmaceuticals, Inc.E: [email protected]P: 650-218-1840Twitter @Pacylex (https://twitter.com/pacylex) LinkedIn (www.linkedin.com/company/pacylex-pharma)Facebook (https://www.facebook.com/pacylex)Reportable page:( https://pacylex.reportablenews.com/ )#cancer, #lymphoma, #leukemia, #albertacancer, #Pacylex, #PCLX001, #UAlberta; #UAlberta_FoMD; #Worldslongestgame, #AACR23, #MDACC, #NHL

Contacts:

Michael Weickert Ph.D

650-218-1840

[email protected]

Source: Pacylex

Distributed by: Reportable, Inc.